Unlearn
2 known investors
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies. The company aims to accelerate drug development and bring treatments to patients faster through precision-driven study design.
Investors · 2
In the news
- Digital twin developer Unlearn sees double with 2nd $50M venture capital roundfiercebiotech.com · 2024
- Unlearn Raises $50M in Series C Fundingfinsmes.com · 2024
- Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technologybusinesswire.com · 2024
- Biotech AI startup Unlearn adds $15 mln and OpenAI CTO to board | Reutersreuters.com · 2023
- Unlearn | Investment | Insight Partnersinsightpartners.com · 2022
- Unlearn.AI Raises $3M Series A Extension Funding - FinSMEsfinsmes.com · 2020